2024
Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition
Rackear M, Quijano E, Ianniello Z, ColĂłn-RĂos D, Krysztofiak A, Abdullah R, Liu Y, Rogers F, Ludwig D, Dwivedi R, Bleichert F, Glazer P. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition. Oncotarget 2024, 15: 699-713. PMID: 39352803, PMCID: PMC11444335, DOI: 10.18632/oncotarget.28651.Peer-Reviewed Original ResearchConceptsTumor targetingMonoclonal antibody therapyTumor-specific targetingCell uptakeNucleic acid bindingCell surface antigensAntibody therapyHuman variantsClinical successCell-penetrating antibodiesAcid bindingSystemic administrationSurface antigensTumorRAD51 inhibitionAntibody platformMechanism of cell penetrationBind RAD51AntibodiesFull-lengthSpecific targetsCell penetrationDisease targetsCellsAutoantibodies
2015
When defense becomes dangerous--transcription factor Nrf2 and cancer.
Krysztofiak A, Krajka-Kuźniak V. When defense becomes dangerous--transcription factor Nrf2 and cancer. Postępy Higieny I Medycyny Doświadczalnej 2015, 69: 140-52. PMID: 25614681.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTranscription factor Nrf2Factor Nrf2Significance of Nrf2Expression of genesProtein Keap1Upstream kinaseRole of Nrf2Activation of Nrf2Nrf2 phosphorylationConformational changesBiotransformation of drugsTreatment of cancerTherapeutic effectCytoprotective enzymesDrug resistanceNrf2Adverse effectsEnzymatic systemsPhase IICancerPotential carcinogensActivationKinaseGenesPhosphorylation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply